Research Studies

A multicenter, randomised, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients (CRLXA): RELAX -2

Start Date

June 2014

End Date

January 2016

Co-ordinated by

Novartis

Local PI

Dr Frank Coffey

Lead Research Practitioner

Sonya Finucane

This study shows that the short-term intravenous infusion of Serelaxin does not improve outcomes when compared with placebo in patients with Heart Failure. Below is a link to the statement released by the sponsor following the results.
https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-rlx030-serelaxin-patients-acute-heart